Report Overview

Indian Hodgkin Lymphoma drug market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Hodgkin's lymphoma is a malignant tumor that develops from cells in the lymphatic system called lymphocytes. The cancer is characterized histologically by the presence of multinucleated giant cells called Reed-Sternberg cells and associated abnormal, smaller mononuclear cells originating from B-lymphocytes in the germinal centers of lymphoid tissue. The age-adjusted incidence rates for NHL in men and women in India are 2.9/100,000 and 1.5/100,000, respectively. Within India, the incidence is several-fold higher in urban cancer registries compared to rural areas; the incidence being higher in metropolitan cities and Indian immigrants suggesting that urban lifestyles and economic progress may increase the cancer incidence.India has an estimated 40,000 sufferers of non-Hodgkins lymphoma. The major drivers are large population base and increasing incidence rate, along with government support.



Market Drivers

The increasing prevalence of cancers of different forms, including blood cancer will aid the lymphoma treatment market growth during the forecast period. The growing necessity for advanced and effective therapeutics can be a crucial factor in boosting the lymphoma treatment market trends. For instance, lymphomas usually have no to minimal symptoms till the cancer hits the last stage and, in that period, an aggressive and efficient therapeutics is required for better clinical outcomes. Furthermore, the requirement for pre-treatment options to administer advanced therapeutics in patients for the treatment of lymphoma will enable healthy growth of the market in the foreseeable future. In addition, the demand for enhanced and better clinical outcomes for patients will create business opportunities for this market during the forecast period. Lymphoma comprises a sizeable number of blood cancer and the significant number of these cancer has no clinical sign till the disease is in the final stages, a need for more robust treatment methods fuel the growth of this market.